Browsing by Author "Giwa H.B"

Now showing 1 - 5 of 5
  • Item
    A Cross-Sectional Study on Health-Related Quality of Life and Productivity Loss in HIV/AIDS Patients on ART
    (Faculty of Science, University of Ilorin, 2025-12-01) Giwa H.B; Oluwaseyi A; Jamiu M.O; Giwa F.S; Giwa A
    This study evaluated health-related quality of life (HRQoL), productivity loss, and associated factors among HIV/AIDS patients on antiretroviral therapy at a tertiary-level hospital in Ilorin, Kwara State, Nigeria. A cross-sectional study was conducted among patients registered in the clinic during the preceding ten years. Data were collected using the World Health Organization Quality of Life HIV Brief (WHOQOL-HIV-BREF) and the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). Of the 358 participants, 94 (26.3%) were male and 264 (73.7%) females. Majority age group were 39-55years 204 (56%). Most respondents were married at 216 (60.3%) and did not perceive themselves as ill 334 (93.2). The overall (HRQoL) score was 59.34%, with 71.34% and 75.05% observed in the psychological and physical domains. Single individuals had increased scores of 30,25, 10 and 20 across HRQoL domains. Work impairment and overall activity impairment scores, as outcomes of work productivity, were found to be 12.81% and 14.35%, respectively. The highest percentage of patients (86.2 %) were on a Dolutegravir (DTG) based regimen, while others were on Atazanavir boosted regimens. Overall HRQol scores showed that participants were coping moderately well but had unmet needs due to chronic nature of the disease. Advanced medical care positively impacts the physical and psychological domains of HRQoL. The disease exerts a mild to moderate impact on productivity. Notably, psychological status shows a stronger association with loss of productivity. Higher HRQoL scores are strongly linked to reduced activity impairment and productivity. Emphasis should be on comprehensive care addressing physical, psychological, environmental and social aspects of HIV.
  • Item
    A Cross-Sectional Study on Health-Related Quality of Life and Productivity Loss in HIV/AIDS Patients on ART
    (Faculty of Physical Sciences,, 2025-09-19) Giwa H.B; Oluwaseyi A; Jamiu M O; Giwa F.S; Giwa A
    This study evaluated health-related quality of life (HRQoL), productivity loss, and associated factors among HIV/AIDS patients on antiretroviral therapy at a tertiary-level hospital in Ilorin, Kwara State, Nigeria. A cross-sectional study was conducted among patients registered in the clinic during the preceding ten years. Data were collected using the World Health Organization Quality of Life HIV Brief (WHOQOL-HIV-BREF) and the Work Productivity and Activity Impairment Questionnaire: General Health (WPAI:GH). Of the 358 participants, 94 (26.3%) were male and 264 (73.7%) females. Majority age group were 39-55years 204 (56%). Most respondents were married at 216 (60.3%) and did not perceive themselves as ill 334 (93.2). The overall (HRQoL) score was 59.34%, with 71.34% and 75.05% observed in the psychological and physical domains. Single individuals had increased scores of 30,25, 10 and 20 across HRQoL domains. Work impairment and overall activity impairment scores, as outcomes of work productivity, were found to be 12.81% and 14.35%, respectively. The highest percentage of patients (86.2 %) were on a Dolutegravir (DTG) based regimen, while others were on Atazanavir boosted regimens. Overall HRQol scores showed that participants were coping moderately well but had unmet needs due to chronic nature of the disease. Advanced medical care positively impacts the physical and psychological domains of HRQoL. The disease exerts a mild to moderate impact on productivity. Notably, psychological status shows a stronger association with loss of productivity. Higher HRQoL scores are strongly linked to reduced activity impairment and productivity. Emphasis should be on comprehensive care addressing physical, psychological, environmental and social aspects of HIV.
  • Item
    Cost of Illness Analysis of Pelvic Inflammatory Disease in Nigeria a Developing Economy
    (2023-04-14) Giwa H.B; Giwa A.; Jamiu M.O,; Busayomi A.; Saadu R.A
    Background: Pelvic inflammatory disease (PID) is a leading cause of infertility, ectopic pregnancies and psychological trauma, thus, representing a major public health concern and high economic burden for women in their reproductive ages. Objective: To conduct cost of illness analysis (COI) of PID in patients in University of Ilorin, Teaching Hospital, Ilorin, Kwara state, North- central Nigeria. Methods: A one year retrospective review of 2560 case notes of PID patients of which 396 were selected as the sample size from January 2021 to December 2021, in outpatient clinic of university of Ilorin teaching hospital. The selection of the 396 cases was done using systematic random sampling with sample interval of 5. Cost of Illness was determined by prevalence rate method, using direct costs only. Results: The annual cost of illness for the 396 PID patients on antibiotics was N4,418,16310,646 USD with drugs, diagnostic/monitoring tests, transportation, consultation fees and personnel cost components of 1,780 USD (16.73%), 4,161 USD (39.09%),666USD (6.26%),1778(16.70%), 2259 USD( 21.22%) respectively. The annual average national cost of illness of PID was N 11, 156.97 (26.86 USD) Conclusion: The annual average national cost of illness of PID represents 30.9 % of annual health expenditure per capita. This is not particularly high when compared with PID COI estimates achieved for some developed countries. The Annual National cost of illness for PID in Nigeria, a developing economymay beabout 69 million USD annually
  • Item
    Impact of Knowledge and Practice of Lifestyle/dietary Modification on Quality of Life of Hypertensive Patients: A Randomised Controlled Study
    (Penerbit Universiti Sains Malaysia (University of Science Malaysia Press), 2025-04-30) Jamiu M.O; Abdulazeez I.F; Giwa H.B
    Hypertension (HTN) is a leading cause of disability and death in both developing and developed countries with lifestyle/dietary modification playing a strong role in both prehypertension and hypertensive state. The research was carried out among 317 patients at University of Ilorin Teaching Hospital, Nigeria, who were randomised into control (158) and intervention (159) groups. Intervention was carried out after baseline study and 6 months with evaluation at 6 months and 12 months. A self-developed standardised questionnaire, with a Cronbach’s alpha of 0.849, was used to assess patients’ knowledge, while quality of life was evaluated using the World Health Organization Quality-of-Life Scale (WHOQOLBREF) standardised questionnaire. A total of 136 participants in the control group and 139 in the intervention group completed the study. The mean age of the patients was 59.2 ± 12.5 with male = 141 (44.5%) while female = 176 (55.5%). Baseline characteristics were comparable. Following intervention, 6 months and 12 months knowledge difference was significant (p < 0.001). A significantly different practice in physical activity (p < 0.001) was observed at 6 months while all the four area of practice were significantly different at 12 months. The practice of dietary modification in the intervention group was similarly significantly different in the intervention group at 6 months and 12 months (p < 0.05). Significant reduction in alcohol intake (p < 0.001), dietary sodium (p < 0.001) and increase in physical activity were associated with improved quality of life but, not reduction in sugar intake (p = 0.325). Good practice of lifestyle and dietary modification was found to improve quality of life among hypertensive patient
  • Item
    Preliminary Quality Evaluation of New Generic Brands of Ciprofloxacin Tablets
    (INTERNATIONAL JOURNAL OF SCIENCE FOR GLOBAL SUSTAINABILITY ( A Publication of Faculty of Science, Federal University Gusau Nigeria), 2025-10) Eniayewn O.I; Faidat F.M; Afosi ÆB; Bamidele O.D; Abdullahi S.T; Aiyelero O.M; Giwa H.B
    Routine quality assessment is essential to ensure safety, e&cacy, and compliance with pharmacopeial standards. This study evaluated six newly marketed generic brands of ciproßoxacin 500 mg tablets using in-vitro quality control tests. In-vitro quality control tests including weight uniformity, thickness, hardness, friability, and disintegration were performed in accordance with the British Pharmacopoeia standards. The ciproßoxacin content was determined using ultraviolet (UV) spectrophotometry (USP Monograph). All brands exhibited uniform white color, consistent shape, and intact markings with no evidence of breakage. Weight uniformity testing confirmed compliance with United States Pharmacopeia (USP) limits, although mean weight differences across brands were statistically significant (p= 0.0001). Tablet thickness showed minimal deviation (SD = 0.03—0.26) but significant inter-brand variation (p = 0.001). Hardness values fell within the 40—100 N range for all except Brand D; ANOVA revealed significant differences between brands (p = 0.001). Friability was below the USP threshold of l% for all brands, with Brands E and F recording 0.00%. All brands coippletely disintegrated within 30 minutes, indicating acceptable in-vitro performance. Drug content assay showed that Brands B (103.6%), D (102.1%), E (99.9%), and F (101%) complied with USP specifications (9Œ-110%), while Brands A(77.4%) and C (89.3%) failed. In conclusion, most evaluated generics demonstrated satisfactory pharmaceutical quality; however, the failure of two brands in drug content assay underscores the need for routine post-market surveillance to safeguard therapeutic equivalence of ciprofloxacin tablets. Keywords: Ciprofloxacin, generics„ quality assessment, tablets